Benzinga · Sep 8, 2026
Acurx Pharmaceuticals Files Prospectus For 1.5M Offering
-SEC Filing
AC
NASDAQ · ACXP
Acurx Pharmaceuticals, Inc.
Healthcare · Biotechnology
$1.40
Up+$0.00 (+0.00%)
Updated Sep 12, 2026, 11:42 AM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 2.38M
- P/E ratio
- -0.27
- Dividend yield
- 0.00%
- 52-week range
- $1.31 – $7.54
- Volume
- 64.71K
- Avg. volume
- 61.79K
Price performance
ACXP price history
1M range · 20 trading sessions · Daily adjusted prices
ACXP closed at $1.40 after 20 trading sessions, up 0.36% for the selected period.
- Last close
- $1.40
- Period change
- +0.36%
- Period low
- $1.40
- Period high
- $1.65
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $1.41 | $1.41 | $1.38 | $1.40 | 64.71K |
| Sep 10, 2026 | $1.41 | $1.425 | $1.38 | $1.40 | 58.78K |
| Sep 9, 2026 | $1.4127 | $1.43 | $1.41 | $1.41 | 32.57K |
| Sep 8, 2026 | $1.41 | $1.46 | $1.41 | $1.43 | 88.57K |
| Sep 4, 2026 | $1.40 | $1.42 | $1.3901 | $1.42 | 47.68K |
| Sep 3, 2026 | $1.42 | $1.42 | $1.39 | $1.40 | 51.59K |
| Sep 2, 2026 | $1.41 | $1.44 | $1.40 | $1.43 | 82.53K |
| Sep 1, 2026 | $1.43 | $1.43 | $1.38 | $1.40 | 109.68K |
| Aug 31, 2026 | $1.44 | $1.45 | $1.40 | $1.45 | 111.68K |
| Aug 28, 2026 | $1.47 | $1.47 | $1.42 | $1.44 | 69.74K |
| Aug 27, 2026 | $1.43 | $1.4785 | $1.42 | $1.46 | 86.86K |
| Aug 26, 2026 | $1.42 | $1.46 | $1.39 | $1.43 | 146.08K |
| Aug 25, 2026 | $1.41 | $1.445 | $1.40 | $1.41 | 87.73K |
| Aug 24, 2026 | $1.47 | $1.49 | $1.395 | $1.40 | 132.65K |
| Aug 21, 2026 | $1.45 | $1.53 | $1.45 | $1.47 | 84.59K |
| Aug 20, 2026 | $1.41 | $1.46 | $1.39 | $1.45 | 132.2K |
| Aug 19, 2026 | $1.45 | $1.489 | $1.37 | $1.44 | 269.23K |
| Aug 18, 2026 | $1.57 | $1.65 | $1.405 | $1.44 | 267.7K |
| Aug 17, 2026 | $1.40 | $1.8172 | $1.3883 | $1.65 | 1.1M |
| Aug 14, 2026 | $1.43 | $1.44 | $1.31 | $1.395 | 613.89K |
Latest ACXP news
The latest Smart Investors Daily articles mentioning ACXP.
Stock researchCompany · Overview
ACXP research
Overview
Company profile and research snapshot.
Company profile
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 30, 2025 | HC Wainwright & Co. | Buy | — |
| Aug 12, 2025 | HC Wainwright & Co. | Buy | — |
| Mar 19, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 13, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 10, 2025 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 17, 2026
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat
Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proposed proprietary, or brand name, CIFBEZY for ibezapolstat, the Company's lead antibiotic product candidate being developed for both the acute treatment and the reduction of recurrence of CDI. The Company als
Benzinga · Aug 17, 2026
FDA Conditionally Accepts Acurx Pharmaceuticals' Brand Name CIFBEZY for Ibezapolstat
The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTOThese initial milestones will form the basis for the commercial
Yahoo · Aug 14, 2026
Acurx Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary
Moby summary of Acurx Pharmaceuticals, Inc.'s Q2 2026 earnings call
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
